Summary:
In patients with obesity-related heart failure with preserved ejection fraction (HFpEF) enrolled in the STEP-HFpEF trials (n=1,145), weekly semaglutide 2.4 mg significantly reduced NT-proBNP levels, improved health status (up to 11.9 points in KCCQ), and achieved consistent weight loss compared to placebo under identical conditions.
| PICO | Description |
|---|---|
| Population | Patients with obesity-related heart failure with preserved ejection fraction (HFpEF), enrolled in the STEP-HFpEF and STEP-HFpEF DM trials; total of 1,145 participants. |
| Intervention | Administration of semaglutide 2.4 mg weekly to examine reductions in NT-proBNP levels, health status improvements, and weight loss. |
| Comparison | Placebo-controlled group used to evaluate semaglutide’s efficacy on NT-proBNP levels and health outcomes, while undergoing identical trial conditions. |
| Outcome | Semaglutide significantly reduced NT-proBNP levels. Greater improvements in health status were observed in participants with higher baseline NT-proBNP tertiles (up to 11.9 points in the Kansas City Cardiomyopathy Questionnaire). Reductions in body weight were consistent across all groups, demonstrating efficacy regardless of baseline values. |
Source: Mark C. Petrie, et al. “Semaglutide and NT-proBNP in Obesity-Related HFpEF: Insights From the STEP-HFpEF Program.” J Am Coll Cardiol. Read article here.
